KL1 Internal Repeat Mediates Klotho Tumor Suppressor Activities and Inhibits bFGF and IGF-I Signaling in Pancreatic Cancer

Lilach Abramovitz1, Tamar Rubinek1, Hagai Ligumsky1,3, Shikha Bose4, Iris Barshack2,3, Camila Avivi2, Bella Kaufman1, and Ido Wolf1,3

Abstract

Purpose: Klotho is a transmembrane protein which can be shed, act as a circulating hormone and modulate the insulin-like growth factor (IGF)-I and the fibroblast growth factor (FGF) pathways. We have recently identified klotho as a tumor suppressor in breast cancer. Klotho is expressed in the normal pancreas and both the IGF-I and FGF pathways are involved in pancreatic cancer development. We, therefore, undertook to study the expression and activity of klotho in pancreatic cancer.

Experimental Design: Klotho expression was studied using immunohistochemistry and quantitative RT-PCR. Effects of klotho on cell growth were assessed in the pancreatic cancer cells Panc1, MiaPaCa2, and Colo357, using colony and MTT assays and xenograft models. Signaling pathway activity was measured by Western blotting.

Results: Klotho expression is downregulated in pancreatic adenocarcinoma. Overexpression of klotho, or treatment with soluble klotho, reduced growth of pancreatic cancer cells in vitro and in vivo, and inhibited activation of the IGF-I and the bFGF pathways. KL1 is a klotho subdomain formed by cleavage or alternative splicing. Compared with the full-length protein, KL1 showed similar growth inhibitory activity but did not promote FGF23 signaling. Thus, its administration to mice showed favorable safety profile.

Conclusions: These studies indicate klotho as a potential tumor suppressor in pancreatic cancer, and suggest, for the first time, that klotho tumor suppressive activities are mediated through its KL1 domain. These results suggest the use of klotho or KL1 as potential strategy for the development of novel therapeutic interventions for pancreatic cancer.

Introduction

Pancreatic adenocarcinoma is the fourth leading cause of cancer death in the Western world, and despite recent advances, the median survival time after diagnosis of metastatic disease remains less than 6 months (1, 2). The insulin-like growth factor (IGF)-I and the fibroblast growth factor (FGF) pathways play important roles in the development of this cancer (3, 4). The IGF-I pathway promotes tumorigenesis of various malignancies, and excessive activation of the IGF-I receptor (IGF-IR) is associated with malignant transformation, increased tumor aggressiveness, and protection from apoptosis (3, 5, 6). IGF-I and IGF-IR are often overexpressed in human pancreatic tumors and cell lines, and inhibition of the IGF-I pathway suppresses tumorigenicity and increases sensitivity of pancreatic tumors to radiation and chemotherapy (7, 8). Targeted therapies directed against the IGF-IR are currently being tested for the treatment of pancreatic cancer in clinical trials (http://clinicaltrials.gov/). The FGF pathway is involved in various stages of cancer development, including mitogenesis, cell differentiation, and angiogenesis (4, 9). Increased expression of FGF receptors (FGFR) and the ligands FGF-1, -2, -5 and -7 was noted in pancreatic cancer samples and cell lines, and high expression of FGF-2 [also termed basic FGF (bFGF)] was associated with a more advanced tumor stage and shorter survival (10). Moreover, exogenous FGF-2, -5, and -7 exert mitogenic activity toward pancreatic cells (10, 11).

Human klotho (hKL) is a 1012-amino acid single-pass transmembrane protein, which is abundantly expressed in the distal convoluted renal tubules of the kidney and the choroid plexus in the brain, and also present in various exocrine and endocrine tissues, including the pancreas (12–15). The extracellular domain of klotho is composed of 2 internal repeats, KL1 and KL2, that share amino-acid sequence homology to β-glucosidase but lack glucosidase activity (15). KL1 may also be transcribed through an alternative splicing (15). Klotho

Authors’ Affiliation: 1Institute of Oncology, 2Department of Pathology, The Chaim Sheba Medical Center, Ramat-Gan, Israel; 3Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; and 4Department of Anatomic Pathology, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, California

Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

Corresponding Author: Ido Wolf, Institute of Oncology, The Sheba Medical Center, Ramat-Gan, Israel, 52621. Phone: 972-52-666-9150; Fax: 972-3-530-2083; E-mail: wolf-i@inter.net.il

doi: 10.1158/1078-0432.CCR-10-2749
©2011 American Association for Cancer Research.
We have recently identified klotho as a tumor suppressor in breast cancer. In this study, we show that klotho expression is reduced in human pancreatic adenocarcinoma, and treatment with klotho or with KL1 internal repeat effectively slow growth of pancreatic cancer cells in vitro and in vivo. Moreover, long-term administration of KL1 to mice shows a favorable toxicity profile. As klotho is an endogenous hormone, its administration is potentially feasible and may serve as a novel therapy for pancreatic, as well as other cancers.

As diagnosis of pancreatic cancer is often cytology-based, the identification of reliable histological markers is of utmost importance. Our expression analysis suggests that loss of klotho may serve as novel diagnostic marker for this disease.

Materials and Methods

Chemicals, antibodies, and constructs
The chemicals used were bFGF (Biological Industries), IGF-I, and soluble human KL1 (hKL1; PeproTech Inc); 5-fluorouracil (5-FU; Sigma), soluble hKL (R&d Systems), G418 (Invitrogen), and gemcitabine (Eli Lilly). Antibodies used were phospho-AKT1 (S473), phospho-IGF-IR (Y1131), phospho-FRS2α (Y196), total pan-AKT (Cell Signaling Technology), diphosphorylated and total-ERK1/2 (Sigma), phospho-IRS1 (Invitrogen), total IRS1 (Upstate), HA (Covance), and klotho (Calbiochem). Klotho expression vector was a generous gift of Y. Nabeshima (Kyoto University).

Immunohistochemistry analysis
Pancreatic cancer sections were created, after Institutional Review Board (IRB) approval, from 18 pancreatic cancer samples and 5 normal pancreas samples, diagnosed at Sheba Medical Center and Cedars-Sinai Medical Center. Staining was conducted as described (12) and scored by percent of positive tumor cells and staining intensity. Negative and low expressions were categorized low, whereas intermediate and high expressions were categorized as high.

Cells and transfections
Panc1, MiaPaCa2, and Colo357 pancreatic adenocarcinoma cell lines, the pancreatic neuroendocrine tumor (NET) cancer cell line BON-1 and the noncancerous HEK-293 were obtained from the American Type Culture Collection. All transfections used LipofectAMINE 2000 (Invitrogen).

Quantitative reverse transcription PCR
Total RNA extraction, cDNA production, and quantitative reverse transcription PCR (RT-PCR) were carried out as described (12). Total RNA of human normal pancreas was obtained from BioChain. cDNA from pancreatic adenocarcinoma tumor and normal tissue adjacent to the tumor were obtained from the Institutional Tissue Bank of the Sheba Medical Center after IRB approval.

Western blot analysis
Protein extraction and Western blotting was conducted as described (12).

Colony assays
Two days following transfection with the indicated plasmids, G418 (900 μg/mL for Panc1, 1,000 μg/mL for MiaPaCa2, and 750 μg/mL for Colo357, HEK-293, and BON1) was added to the culture media. At day 14, cells were stained using crystal violet (Sigma) and quantitated as described (12).

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (MTT)
Cells/well (3,000) were plated in 96-well plates, cultured in the appropriate culture media, and treated for 48 hours as indicated. MTT assay was carried out as done previously (12).

www.aacrjournals.org Clin Cancer Res; 17(13) July 1, 2011 4255
Published OnlineFirst May 13, 2011; DOI: 10.1158/1078-0432.CCR-10-2749

Published OnlineFirst May 13, 2011; DOI: 10.1158/1078-0432.CCR-10-2749
Soft agar assay

To determine the effect of klotho on anchorage-independent growth, 15,000 Panc1 cells per well were cultured in Noble agar (Sigma) at a final concentration of 0.3%, on top of 0.5% base agar. The cells were seeded in triplicate wells of 6-well plates, and re-fed twice a week with growth medium containing hKL (0.8 pM) or control vehicle. Colonies were counted after 21 days, following staining with 0.005% crystal violet.

Generation of soluble mouse klotho

Soluble mouse klotho (mKL) was generated as described (16).

Genetic analyses for the KL-VS variant

Genotyping the KL-VS variant was carried out as described (20).

Animal studies

Mice maintenance and experiments were carried out under institutional guidelines of the Sheba Medical Center. Panc1 cells were prepared as described (21). For the experiment with mKL: 6-week-old female athymic nude mice were injected with cells (0.5 × 10⁶) subcutaneously into both flanks. After 5 days, mice were treated with daily intraperitoneal injections of mKL: 10 μg/kg, 25 μg/kg, or saline control (n = 5 per group). Tumor size was measured with a digital caliper for up to 5 weeks, and the volume was estimated using the equation \( V = \left( a \times b^2 \right) \times 0.5236 \), where \( a \) is the larger dimension and \( b \) the perpendicular diameter. hKL treatment experiment was carried out as described above with the following minor exceptions: One flank was injected, and mice were treated with 2.5 μg/kg hKL, 10, 25 μg/kg hKL1 or vehicle control (n = 6–7 for each treatment group, n = 12 for the control group). For the experiment with MiaPaCa2 cells, 0.75 × 10⁶ cells were injected into both flanks. Mice (n = 8 per group) were treated with 2.5 μg/kg hKL, 10 μg/kg hKL1, or vehicle control.

Statistical analysis

Results are presented as mean ± SD. Categorized variables were compared between the study groups using Fisher’s exact test and continuous variables were compared using t test. All significance tests were 2-tailed and a \( P < 0.05 \) was considered as statistically significant. The nature of interaction between klotho and 5-FU or gemcitabine was analyzed using the additive model (22). A ratio between the observed and the predicted viability was calculated for all combinations and a ratio less than 0.8 for the interaction was considered to be synergistic.

Results

Expression pattern of klotho in normal pancreas and pancreatic adenocarcinoma

While high klotho mRNA expression was noted in whole pancreas extracts (23), the expression pattern of klotho in different components of the normal pancreas or in pancreatic cancer are currently unknown. We conducted immunohistochemistry analysis of klotho expression in pancreatic tissues, using an antibody directed against the intracellular domain of klotho, as previously described (12). Normal human kidney sections served as control and positive staining was noted only in the distal convoluted tubules (12). Analysis of 5 normal pancreas samples revealed high klotho expression in the exocrine pancreatic ducts, lower expression in the islet cells, and no expression in the surrounding stromal tissue (Fig. 1A). Analysis of 18 pancreatic adenocarcinoma samples revealed reduced klotho expression in 15 (83%) of the samples: no expression in 9 and low expression in 6 samples (Fig. 1B, Table 1, \( P = 0.002 \) for the comparison between normal and cancer samples).

Klotho expression was also analyzed using quantitative RT-PCR in normal human pancreatic tissue and 3 pancreatic adenocarcinoma cell lines: Panc1 and MiaPaCa2, which represent poorly differentiated adenocarcinoma, and Colo357, which represent moderately differentiated cancer (24). Significantly lower klotho mRNA levels were observed in the cancer cells: 12% in Panc1 and less than 1% in MiaPaCa2 and Colo357 cells compared with the normal tissue (Fig. 1C). Klotho mRNA levels were then measured in 5 adenocarcinoma samples and adjacent normal pancreatic tissue. Samples were obtained during pancreatic surgery and the presence of adenocarcinoma was verified by an experienced pathologist. Reduced klotho expression in the tumor compared with normal pancreas was noted in 4 (80%) of the samples (Fig. 1D).

Recently, silencing of klotho by promoter hypermethylation was noted in cervical cancer (25), and we noted epigenetic silencing of klotho in breast cancer cells and clinical samples (Rubinek and colleagues, submitted for publication). We tested the presence of methylation in the promoter of klotho using methylation-specific PCR (MSP) directed against a region within the CpG island in the klotho promoter. In correlation with the expression pattern (Fig. 1C), we noted the klotho promoter to be fully methylated in Colo357 and MiaPaCa2 and hemi-methylated in Panc1 cells (Supplementary Fig. S2). Genetic analysis (data not shown) revealed that while wild-type klotho gene was found in MiaPaCa2 and Colo357, only the less active klotho variant, KL-VS (20), was detected in Panc1.

Klotho inhibits growth of pancreatic cancer cells in vitro and in vivo

The effect of klotho overexpression on growth of pancreatic cancer cells was assessed using colony formation assays. Colo357, MiaPaCa2, and Panc1 pancreatic cancer cells, pancreatic NET cell line BON1 (26), and the non-cancerous HEK-293 cells were transfected with either a HA-tagged klotho expression vector (pcDNA3-HA-KL) or an empty vector (pcDNA3). Transfected cells were cultured in media containing G418 for 2 weeks and stained to determine the number of surviving colonies. Klotho expression...
reduced the number and size of surviving colonies of the pancreatic adenocarcinoma and BON1 cells (Fig. 2A), but did not affect growth of HEK-293 cells ([12] and data not shown).

Klotho may be shed and act as a circulating hormone, and we and others have shown that either soluble klotho or conditioned medium taken from klotho overexpressing cells is active (12, 15, 23, 27). We, therefore, tested the ability of soluble klotho to inhibit proliferation of pancreatic cancer cells. Cells were treated with mKL, generated as described (12), or commercially available hKL. The cells were seeded on 96-well plates, treated with either mKL or hKL for 48 hours, and viability was assayed by MTT assay. Both mKL and hKL were found to be active and reduced viability of Panc1 cells by 70% and 55%, respectively (*P < 0.005 for the comparison between the compound and the control). mKL was also tested against Colo357 and MiaPaCa2 and found to be active, albeit to a lesser extent (40% reduction in viability, *P < 0.01, Fig. 2E and F).

Anchorage-independent growth is a hallmark of the neoplastic phenotype. Importantly, soft agar assays revealed that treatment with klotho significantly inhibited anchorage-independent growth of Panc1 (Fig. 2C).

5-FU and gemcitabine are chemotherapeutic drugs commonly used for the treatment of pancreatic cancer (28). The ability of klotho to enhance their activity on pancreatic cancer cells was examined. Panc1, MiaPaCa2, and Colo357 cells were treated for 48 hours with klotho, 5-FU or gemcitabine, their combination, or a control vehicle, and viability was assayed. The addition of klotho significantly increased the activity of 5-FU (Fig. 2D–F). The nature of the interaction between mKL and 5-FU was analyzed using the additive model (22). The combination of mKL

<p>| Table 1. Klotho expression in normal pancreas and pancreatic adenocarcinoma samples |
|---------------------|---------------------|---------------------|</p>
<table>
<thead>
<tr>
<th>Klotho expression</th>
<th>Normal Pancreas (n = 5)</th>
<th>Pancreatic adenocarcinoma (n = 18)</th>
</tr>
</thead>
<tbody>
<tr>
<td>High</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Low</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>Absent</td>
<td>0</td>
<td>9</td>
</tr>
</tbody>
</table>
(6 nmol/L) and 5-FU (500 μmol/L) showed a sub-additive effect in MiaPaCa2 and Colo357, whereas a synergistic effect was noted in Panc1 cells (Fig. 2D and Supplementary Table S1). The combined treatment of hKL (0.8 pM) with gemcitabine (100 nmol/L) had a minor effect on Panc1 cells (Fig. 2G) and Colo357 (data not shown), showing a sub-additive effect (Supplementary Table S2), whereas a synergistic effect was noted for the combination of 0.8 pM hKL with 1 nmol/L gemcitabine in MiaPaCa2 cells (Fig. 2H and Supplementary Table S2).

To test the in vivo activity of klotho, Panc1 cells were injected into both flanks of nude mice (0.5 × 10^6 cells per injection), and the mice were treated with intraperitoneal injections of either a control vehicle (n = 5) or mKL 10 μg/kg (n = 5) or 25 μg/kg mKL (n = 5), 5 days a week for 5 weeks. Treatment with klotho did not affect weight (Fig. 2I) or general health of the mice, but significantly reduced tumor size (Fig. 2J, **P < 0.05 for comparison between treated and control groups).

**Klotho inhibits activation of the IGF-I pathways in pancreatic cancer cells**

The IGF-I pathway plays an important role in the development of pancreatic cancer and klotho inhibits activation of this pathway (8, 12). Panc1, MiaPaCa2, and Colo357 cells express high levels of the IGF-IR and show enhanced proliferation following IGF-I treatment (7, 8). We examined the ability of klotho to inhibit activation of the IGF-I pathway in these cells. For these studies, cells were transfected with either pcDNA3-HA-KL or an empty vector, starved for 48 hours, treated with IGF-I (12.5 nmol/L for 15 min), and analyzed using Western blotting for the expression and phosphorylation of the IGF-IR and downstream effectors of the IGF-I pathway (Fig. 3A). Klotho overexpression reduced phosphorylation of the IGF-IR and its downstream targets IRS-1, AKT1, and ERK1/2 in all 3 cell lines. Similarly to klotho overexpression, soluble mKL also inhibited activation of the IGF-IR and its downstream effectors by IGF-I in Panc1 cells (Fig. 3B).
Figure 2. (Continued) (D) Panc1 (E) MiaPaCa2, and (F) Colo357 cells were treated with mKL, 5-FU, their combination, or a control vehicle. Panc1 (G) and MiaPaCa2 (H) cells were treated with hKL, gemcitabine, their combination, or a control vehicle. MTT assay was conducted at 48 hours. Data are shown as mean ± SD of 3 independent experiments. * \( P < 0.05 \) for comparison between treated cells and control, and (**) between klotho and chemotherapeutic drug versus drug alone. I and J, Panc1 cells were injected into both flanks of female athymic nude mice. The mice (\( n = 5 \) per group) were treated with daily intraperitoneal injections of either mKL (10 µg/kg or 25 µg/kg) or vehicle control (saline), for 4 weeks. Mice weight (I) and tumor size (J) were monitored weekly. (\( P < 0.05 \), for tumor volume between treated and control groups by the end of the study).
Figure 3. Downregulation of the IGF-I and FGF pathways by klotho in pancreatic cancer cells. A, cells were transfected with either HA-klotho expression plasmid (HA-KL) or a control vector (pcDNA3); after 24 hours, cells were serum starved for 48 hours and treated with IGF-I. Following treatment, cells were harvested and proteins were resolved and immunoblotted using antibodies as indicated. B, Panc1 cells were starved for 48 hours, treated with klotho (10 min) followed by IGF-I stimulation. Expression and phosphorylation of the IGF-IR, AKT, and ERK1/2 were determined. C, cells were transfected as detailed in (A) starved for 48 hours and stimulated with bFGF. Cell lysates were immunoblotted as indicated. Experiments were repeated at least 3 times, band intensities were quantified, and fold increase is specified for each treatment, relative to control.
Klotho inhibits the bFGF pathway in pancreatic cancer cells

bFGF is overexpressed in pancreatic tumor cell lines and is associated with a more advanced tumor stage and poor prognosis (29, 30), and klotho is a well-established modulator of the FGF pathway (18, 19). To study the effects of klotho on the bFGF pathway in pancreatic cancer, pcDNA3-HA-KL or an empty vector were overexpressed in Panc1, MiaPaCa2, and Colo357 pancreatic cancer cells. Cells were starved for 48 hours, treated with bFGF (10 ng/mL), and analyzed for the expression and activity of ERK1/2, the downstream targets of the FGF pathway. Klotho significantly inhibited activation of the bFGF pathway in all 3 cell lines (Fig. 3C).

KL1 inhibits pancreatic cancer growth

The predominant circulating forms of klotho in humans are the full-length protein (hKL), KL1-cleaved product (hKL1), and a splice variant composed only of KL1 (13, 14, 23). We explored the ability of KL1 to inhibit growth of pancreatic cancer cells, compared with full-length klotho. Panc1 cells were transfected with either a full-length mKL expression vector, mouse KL1 (mKL1) or an empty vector (pcDNA3). Similar growth inhibitory activities were noted for KL1 and the full-length protein (Fig. 4A). The activity of soluble KL1 was also tested. Panc1 cells were treated with either hKL or hKL1 for 48 hours and viability was evaluated by MTT assay. Reduction of viability by 50% was observed following treatment with hKL1 at concentrations 100 times higher than hKL (Fig. 4B, *P < 0.005 for comparison between treated and control cells).

We then examined the in vivo growth inhibitory activity of hKL1, compared with hKL, toward pancreatic cancer cells. Panc1 cells were injected into one flank of athymic mice and mice were treated with intraperitoneal injections of either control vehicle (n = 12), hKL (2.5 μg/kg, n = 7), or hKL1 (10 μg/kg, n = 6; 25 μg/kg, n = 7) 5 days a week for 5 weeks. Klotho treatment significantly inhibited tumor growth (Fig. 4D–E, P < 0.05 for comparison of tumor volume and weight between the control- and klotho-treated groups). Immunohistochemistry analysis of the proliferation marker Ki67 revealed a significant reduction in the percent of proliferating cells in 4 tumors harvested from klotho-treated mice compared with 4 controls (50% compared with 70%, P = 0.02 Fig. 4G). Similar experiment, with minor exceptions, was also carried out using MiaPaCa2 cells. Cells were injected into both flanks of athymic mice and mice were treated with a control vehicle (n = 8), hKL (2.5 μg/kg, n = 8), or hKL1 (10 μg/kg, n = 8). After 4 weeks of treatment, all the injected tumors were observed in the control group, whereas 2 tumors (12%) of the hKL-treated mice and 4 (25%) of the hKL1-treated mice completely regressed (Fig. 4I). Moreover, hKL1 inhibited tumor growth more effectively than hKL (Fig. 4H-I).

To our knowledge, the safety of long-term klotho or KL1 administration has not been determined. No changes in weight (Figs. 2I and 4C; data not shown) or general health were noted in mice treated with either hKL or hKL1. The effects of hKL and hKL1 on blood counts and chemistry were also studied. For these studies, blood was withdrawn from control, hKL-treated (2.5 μg/kg) or hKL1-treated (10 μg/kg) mice, at the same day of killing and tumor harvesting, following 5 weeks of treatment. Treatment with either hKL or KL1 did not affect blood counts or liver function tests (data not shown). Importantly, full-length klotho but not KL1, altered, cholesterol and phosphate levels (Table 2). Glucose levels were determined after fasting in the MiaPaCa2 xenograft experiment. While klotho treatment mildly increased glucose levels, hKL1 did not have any significant effect on glucose level (Table 2).

We next analyzed the effects of KL1 on IGF-I, bFGF and FGF23 signaling. Panc1 cells were transfected with either full length klotho, KL1 or an empty vector, starved for 48 hours, treated with IGF-I (12.5 nmol/L for 15 min) or bFGF (10 ng/mL), and analyzed using Western blotting for the level of expression and phosphorylation of AKT or ERK1/2. KL1 reduced phosphorylation of these proteins to a greater extent than the full-length klotho (Fig. 4I). Yet, KL1 had no effect on the phosphorylation of ERK1/2 following FGF23 stimulation in mouse distal convoluted tubules (MDCT) cell line (Fig. 4K). Thus, hKL and hKL1 present cell-type and pathway-dependent differential activities.

Discussion

Our observations indicate klotho as a tumor suppressor in pancreatic cancer. High klotho expression was observed in normal pancreas, whereas low expression was noted in pancreatic adenocarcinoma. Klotho, either overexpressed or soluble, inhibits activation of the IGF and FGF pathways and slow growth of pancreatic cancer cells in vitro and in vivo. Furthermore, we found that KL1 domain was as active as the full length protein but had more favorable safety profile when administered to mice. Reduced expression of klotho was noted in most pancreatic adenocarcinoma samples and cell lines. In accordance with recent studies showing repression of klotho by epigenetic mechanisms in human cervical carcinoma (25) and breast cancer (Rubinek and colleagues submitted), we noted methylation of the klotho promoter in pancreatic cancer cell lines. Panc1 cells and some of the clinical samples do express klotho. However, our genetic analysis revealed that Panc1 carry only the less active KL-VS variant. Thus, we observed 2 mechanisms that may be involved in reducing the activities of klotho in pancreatic cancer cells—epigenetic silencing and expression of a less active protein.

As tissue diagnosis of pancreatic cancer is often based on cells obtained by fine needle aspiration and is based on cytology rather than on architecture of the tissue (31), sensitive and specific markers that will aid differentiating normal and tumor cells are eagerly sought. We noted universal expression of klotho in normal pancreatic cells
Figure 4. KL1 inhibits growth of pancreatic cancer cells. A, Panc1 cells were transfected with HA-KL, HA-KL1, or pCDNA3 and colony assay was conducted as in Figure 2A. B, viability assay for Panc1 cells treated with either soluble hKL or hKL1. Viability was assessed after 48 hours using MTT assay. Data are shown as mean ± SD of 3 independent experiments. *P < 0.03 for comparison between treatment and control. C–F, Panc1 cells were injected subcutaneously into the right flank of female athymic nude mice. The mice were treated with daily intraperitoneal injections of 2.5 μg/kg hKL, 10, 25 μg/kg hKL1, or vehicle control (saline), for 5 weeks. Twelve mice were used in the control group and 6 to 7 in the klotho-treated groups. C, mice weight and (D) tumor size were monitored weekly and (E and F) tumors weight was measured on day of sacrifice. *P < 0.05 for comparison of tumor volume and weight between the control group and the mice treated with klotho. G, H&E and Ki67 immunostaining (×400 magnification).
and loss of expression in most cancer tissues and cells. Thus, if validated by additional studies, low expression of klotho may serve as a novel diagnostic tool for the differentiation between normal and cancerous pancreatic cells.

The presence of KL-VS in pancreatic cancer cells may suggest a role for the variant in pancreatic cancer development. BRCA1 and BRCA2 mutation carriers have an increased risk of developing pancreatic cancer (32–34). We have recently shown that the KL-VS functional variant exhibits reduced activity and is associated with increased breast cancer risk in BRCA1 mutation carriers (20). As klotho may serve as a potential tumor suppressor, the association of a less active variant with increased risk of pancreatic cancer, especially in high-risk populations, should be further explored.

The IGF-I pathway is active in pancreatic NETs (35). Klotho expression was noted in pancreatic islets and expression of klotho inhibited colony formation in the NET cells BON1. The role of klotho as a tumor suppressor in NET should be further explored.

Soluble klotho compounds and also a conditioned medium obtained from klotho-overexpressing cells effectively inhibit growth of breast (12) and pancreatic cancer cells. Thus, secreted klotho may be involved in mediating growth-inhibitory activities. Yet, the expression of klotho in the normal pancreas tissue surrounding the cancer cells does not impair cancer development. Possible explanations for this phenomenon can be reduced shedding of klotho from normal pancreatic cells or reduced penetration of klotho to the tumor due to the presence of desmoplastic stroma. This stroma is typical to pancreatic cancer islets and in pancreatic cancer cells. Thus, if validated by additional studies, low expression of klotho may serve as a novel diagnostic tool for the differentiation between normal and cancerous pancreatic cells.

Figure 4. (Continued) H, MiaPaCa2 cells were injected into both flanks of athymic mice and treated with daily intraperitoneal injections of 2.5 μg/kg hKL, 10 μg/kg hKL1 or vehicle control, for 5 weeks 8 mice per group (16 tumors). Tumor size (H) was monitored weekly and tumors weight (I) was measured on day of sacrifice. P < 0.05 for comparison of tumor weight between the control group and the mice treated with klotho. (J) Panc1 cells were transfected as described above, and stimulated with IGF-I or bFGF. Cell lysates were immunoblotted with indicated antibodies. Phosphorylated-to-total ratio is calculated relative to pcDNA. (K) MDCT cell line was transfected as described above and stimulated with FGF23. Cell lysates were immunoblotted with phospho and total ERK1/2.

and loss of expression in most cancer tissues and cells. Thus, if validated by additional studies, low expression of klotho may serve as a novel diagnostic tool for the differentiation between normal and cancerous pancreatic cells.

The presence of KL-VS in pancreatic cancer cells may suggest a role for the variant in pancreatic cancer development. BRCA1 and BRCA2 mutation carriers have an increased risk of developing pancreatic cancer (32–34). We have recently shown that the KL-VS functional variant exhibits reduced activity and is associated with increased breast cancer risk in BRCA1 mutation carriers (20). As klotho may serve as a potential tumor suppressor, the association of a less active variant with increased risk of pancreatic cancer, especially in high-risk populations, should be further explored.
plasma proteins of less than 60 kDa poses a short half-life, neal injection (data not shown). While low molecular mass tagged klotho in the blood 6 hours following intraperitoneal injection and inhibition of pancreatic cell proliferation by klotho. For example, while klotho only slightly inhibited the IGF-I pathway may mediate the growth-inhibitory activities of klotho in pancreatic cancer. A possible such mechanism is inhibition of the bFGF pathway (4). Klotho is an inhibitor of the bFGF pathway in HEK293 cells (12, 18, 19) and in pancreatic cancer cells (Figs. 3C and 4I). Moreover, modulation of the bFGF pathway by klotho and B-klotho has also been shown in breast (12) and hepatic cancers, respectively (41), pointing to bFGF as an important mediator of klotho activities. The ERK cascade is downstream of several signaling pathways, including the IGF-I and bFGF pathways. We observed only partial correlation between inhibition of ERK1/2 activation and inhibition of pancreatic cells proliferation for klotho. For example, while klotho only slightly inhibited bFGF-induced ERK1/2 in MiaPaCa2 (Fig. 3C), it effectively inhibited their growth in vitro and in vivo. Thus, additional downstream targets of the IGF-I and bFGF pathways may participate in mediating klotho growth inhibitory activities.

Our in vivo studies indicate klotho as a potential novel therapy against pancreatic cancer. As the in vivo activity was observed following treatment with either human or mKL, produced and purified by different methods, the possibility of a non-specific effect is unlikely. Currently, there is no reliable and readily available method to determine klotho levels in the blood. Therefore, the pharmacokinetic properties of klotho could not be determined. Preliminary data using Western blotting indicate detectable levels of HA-tagged klotho in the blood 6 hours following intraperitoneal injection (data not shown). While low molecular mass plasma proteins of less than 60 kDa poses a short half-life, larger proteins exhibit half-life of several days (42). For example, half-life of injected antibodies may be as long as several weeks. It is therefore possible that the half lives of injected klotho (~125 kDa) or KL1 (~68 kDa) are relatively long. While we injected klotho 5 days a week, a less intense schedule of injection may also be effective.

Structure-function relationships of klotho have not been fully elucidated yet. Klotho is composed of 2 internal repeats, KL1 and KL2, which share amino-acid sequence homology to family 1 glycosidases and can be cleaved, shed and act as a circulating hormone. Cleavage can be mediated by ADAM10 and ADAM17, members of the A disintegrin and metalloproteinase (ADAM) family (27, 43). The cleavage products can be either a 130 kDa protein composed of both KL1 and KL2 or 68 and 64 kDa proteins representing KL1 and KL2, respectively. Moreover, klotho gene can transcribe a secreted form of klotho by alternative RNA splicing encoding only the KL1 domain (13, 14, 23). Only full-length klotho can function as a coreceptor for FGF23 (19, 44). Indeed, KL1 did not affect signaling by FGF23 in MDCT cells (Fig. 4K). Accordingly, we observed hypophosphatemia, which may be attributed to the activity of FGF23, in mice treated with klotho, but not in mice treated with the KL1 domain. These data are supported by a recent clinical observation, where genetic overexpression of klotho in a young girl resulted in hypophosphatemia attributed to abnormal regulation of FGF23 signaling (45). On the other hand, each domain can independently regulate cell-surface expression of TRPV5 and ROMK ion channels (46, 47), and we show here, for the first time, that KL1 is a potent inhibitor of bFGF and IGF-I signaling. Taken together, these observations imply differential activities of klotho and KL1 toward different signaling pathways and in different cell lines. These findings may have implications regarding the ability to use klotho as a therapy. While KL1 may be as effective as the full-length protein for the treatment of cancer, it may have a better safety profile.

**Table 2.** Comparison between blood chemistry levels of the control and mice treated with hKL (2.5 μg/kg) or hKL1 (10 μg/kg)

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>hKL, 2.5 μg/kg</th>
<th>P (C vs. hKL)</th>
<th>hKL1, 10 μg/kg</th>
<th>P (C vs. hKL1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urea, mg/dL</td>
<td>54 ± 8</td>
<td>39 ± 7</td>
<td>0.014</td>
<td>44 ± 3</td>
<td>0.05</td>
</tr>
<tr>
<td>Phosphorous, mg/dL</td>
<td>8 ± 1</td>
<td>5 ± 1</td>
<td>0.004</td>
<td>8 ± 2</td>
<td>0.99</td>
</tr>
<tr>
<td>Cholesterol, mg/dL</td>
<td>103 ± 9</td>
<td>78 ± 8</td>
<td>0.003</td>
<td>106 ± 12</td>
<td>0.8</td>
</tr>
<tr>
<td>Creatinine, mg/dL</td>
<td>0.26 ± 0</td>
<td>0.25 ± 0</td>
<td>0.5</td>
<td>0.31 ± 0</td>
<td>0.03</td>
</tr>
<tr>
<td>Bilirubin, mg/dL</td>
<td>0.1 ± 0</td>
<td>0.1 ± 0</td>
<td>0.9</td>
<td>0.1 ± 0</td>
<td>0.5</td>
</tr>
<tr>
<td>Uric acid, mg/dL</td>
<td>3.40 ± 1.22</td>
<td>3.46 ± 0.3</td>
<td>0.9</td>
<td>5 ± 1</td>
<td>0.1</td>
</tr>
<tr>
<td>SGOT (ATS), IU/L</td>
<td>426 ± 225</td>
<td>384 ± 258</td>
<td>0.8</td>
<td>416 ± 290</td>
<td>0.96</td>
</tr>
<tr>
<td>SGPT (ALT), IU/L</td>
<td>70 ± 39</td>
<td>57 ± 39</td>
<td>0.61</td>
<td>103 ± 70</td>
<td>0.4</td>
</tr>
<tr>
<td>Glucose, mg/dL</td>
<td>89 ± 17</td>
<td>106 ± 19</td>
<td>0.08</td>
<td>91 ± 15</td>
<td>0.8</td>
</tr>
</tbody>
</table>

*aGlucose values of mice after fasting from experiment shown in Figure 4H and I.

Several mechanisms may govern klotho growth-inhibitory activities. The IGF-I pathway plays an important role in pancreatic cancer development (37, 38) and klotho is a potent inhibitor of the IGF-I pathway in breast (12), lung (39, 40), and pancreatic cancers. Mechanisms other than inhibition of the IGF-I pathway may mediate the growth-inhibitory activities of klotho in pancreatic cancer. A possible such mechanism is inhibition of the bFGF pathway (4). Klotho is an inhibitor of the bFGF pathway in HEK293 cells (12, 18, 19) and in pancreatic cancer cells (Figs. 3C and 4I). Moreover, modulation of the bFGF pathway by klotho and B-klotho has also been shown in breast (12) and hepatic cancers, respectively (41), pointing to bFGF as an important mediator of klotho activities. The ERK cascade is downstream of several signaling pathways, including the IGF-I and bFGF pathways. We observed only partial correlation between inhibition of ERK1/2 activation and inhibition of pancreatic cells proliferation for klotho. For example, while klotho only slightly inhibited bFGF-induced ERK1/2 in MiaPaCa2 (Fig. 3C), it effectively inhibited their growth in vitro and in vivo. Thus, additional downstream targets of the IGF-I and bFGF pathways may participate in mediating klotho growth inhibitory activities.

Our in vivo studies indicate klotho as a potential novel therapy against pancreatic cancer. As the in vivo activity was observed following treatment with either human or mKL, produced and purified by different methods, the possibility of a non-specific effect is unlikely. Currently, there is no reliable and readily available method to determine klotho levels in the blood. Therefore, the pharmacokinetic properties of klotho could not be determined. Preliminary data using Western blotting indicate detectable levels of HA-tagged klotho in the blood 6 hours following intraperitoneal injection (data not shown). While low molecular mass plasma proteins of less than 60 kDa poses a short half-life, larger proteins exhibit half-life of several days (42). For example, half-life of injected antibodies may be as long as several weeks. It is therefore possible that the half lives of injected klotho (~125 kDa) or KL1 (~68 kDa) are relatively long. While we injected klotho 5 days a week, a less intense schedule of injection may also be effective.

Structure-function relationships of klotho have not been fully elucidated yet. Klotho is composed of 2 internal repeats, KL1 and KL2, which share amino-acid sequence homology to family 1 glycosidases and can be cleaved, shed and act as a circulating hormone. Cleavage can be mediated by ADAM10 and ADAM17, members of the A disintegrin and metalloproteinase (ADAM) family (27, 43). The cleavage products can be either a 130 kDa protein composed of both KL1 and KL2 or 68 and 64 kDa proteins representing KL1 and KL2, respectively. Moreover, klotho gene can transcribe a secreted form of klotho by alternative RNA splicing encoding only the KL1 domain (13, 14, 23). Only full-length klotho can function as a coreceptor for FGF23 (19, 44). Indeed, KL1 did not affect signaling by FGF23 in MDCT cells (Fig. 4K). Accordingly, we observed hypophosphatemia, which may be attributed to the activity of FGF23, in mice treated with klotho, but not in mice treated with the KL1 domain. These data are supported by a recent clinical observation, where genetic overexpression of klotho in a young girl resulted in hypophosphatemia attributed to abnormal regulation of FGF23 signaling (45). On the other hand, each domain can independently regulate cell-surface expression of TRPV5 and ROMK ion channels (46, 47), and we show here, for the first time, that KL1 is a potent inhibitor of bFGF and IGF-I signaling. Taken together, these observations imply differential activities of klotho and KL1 toward different signaling pathways and in different cell lines. These findings may have implications regarding the ability to use klotho as a therapy. While KL1 may be as effective as the full-length protein for the treatment of cancer, it may have a better safety profile.
In summary, this study identified klotho as a potential tumor suppressor and indicated the full-length protein, as well as the KL1, as growth inhibitors and modulators of the IGF-I and bFGF pathways in pancreatic adenocarcinoma. Klotho and KL1 are endogenous circulating hormones and their administration to mice was safe and effectively inhibited growth of pancreatic cancer cells in vivo. The role of klotho and KL1 as novel therapeutic approaches for the treatment of pancreatic adenocarcinoma, as well as other malignant diseases, should be further explored.

Disclosure of Potential Conflicts of Interest

No potential conflict of interests were disclosed.

Acknowledgments

We thank Abraham Czerniak, Amir Onn and Yehudith Cohen for their tremendous help in providing samples from the Institutional Tissue Bank of the Sheba Medical Center.

Grant Support

This research was supported by the Radoshitzky Family in memory of Yoram; the Chief Scientist Office of the Ministry of Health, Israel (grant no. 4055-3 to I. Wolf); the Israel Cancer Association Research Grant by Peter & Nancy Brown in memory of Eric & Melvin Brown; the "Talpiot" Sheba Career Development Award (for IW); and the Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.

References


KL1 Internal Repeat Mediates Klotho Tumor Suppressor Activities and Inhibits bFGF and IGF-I Signaling in Pancreatic Cancer

Lilach Abramovitz, Tamar Rubinek, Hagai Ligumsky, et al.

Clin Cancer Res  Published OnlineFirst May 13, 2011.

Updated version  Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-10-2749

Supplementary Material  Access the most recent supplemental material at: http://clincancerres.aacrjournals.org/content/suppl/2011/05/13/1078-0432.CCR-10-2749.DC1

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.